MiNK Therapeutics Files 8-K on Financials
Ticker: INKT · Form: 8-K · Filed: Mar 21, 2024 · CIK: 1840229
Sentiment: neutral
Topics: financial-reporting, corporate-actions
TL;DR
MiNK Therapeutics dropped an 8-K detailing financials - check it out.
AI Summary
MiNK Therapeutics, Inc. filed an 8-K on March 21, 2024, reporting on its results of operations and financial condition. The filing also includes financial statements and exhibits. The company was formerly known as AgenTus Therapeutics, Inc., with a name change effective January 12, 2021.
Why It Matters
This 8-K filing provides investors with crucial updates on MiNK Therapeutics' financial health and operational status, enabling informed investment decisions.
Risk Assessment
Risk Level: low — This is a routine 8-K filing for financial reporting and does not indicate any immediate or significant risks.
Key Players & Entities
- MiNK Therapeutics, Inc. (company) — Registrant
- AgenTus Therapeutics, Inc. (company) — Former Company Name
- March 21, 2024 (date) — Date of Report
- January 12, 2021 (date) — Date of Name Change
- 149 Fifth Avenue, Suite 500 New York, New York 10010 (address) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on MiNK Therapeutics, Inc.'s Results of Operations and Financial Condition, and to include Financial Statements and Exhibits.
When was MiNK Therapeutics, Inc. formerly known as?
MiNK Therapeutics, Inc. was formerly known as AgenTus Therapeutics, Inc.
On what date did the company change its name?
The company's name change from AgenTus Therapeutics, Inc. to MiNK Therapeutics, Inc. was effective on January 12, 2021.
What is the principal executive office address for MiNK Therapeutics, Inc.?
The principal executive office address is 149 Fifth Avenue, Suite 500, New York, New York 10010.
What is the SIC code for MiNK Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for MiNK Therapeutics, Inc. is 2836, which corresponds to BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
Filing Stats: 517 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2024-03-21 07:00:20
Key Financial Figures
- $0.00001 — ange on which registered Common Stock, $0.00001 par value per share INKT The NASDAQ Cap
Filing Documents
- f8k_032124.htm (8-K) — 15KB
- exh_991.htm (EX-99.1) — 42KB
- 0001171843-24-001514.txt ( ) — 259KB
- gnw-20190101.xsd (EX-101.SCH) — 3KB
- gnw-20190101_def.xml (EX-101.DEF) — 25KB
- gnw-20190101_lab.xml (EX-101.LAB) — 33KB
- gnw-20190101_pre.xml (EX-101.PRE) — 22KB
- f8k_032124_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On March 21, 2024, MiNK Therapeutics, Inc. announced its financial results for the quarter and year ended December 31, 2023. In connection with the announcement, the Company issued a press release, which is being furnished as Exhibit 99.1 to this current report on Form 8-K. The information set forth under Item 2.02 and in Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibit The following exhibit is furnished herewith: 99.1 Press Release dated March 21, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MiNK Therapeutics, Inc. Date: March 21, 2024 By: /s/ Christine M. Klaskin Christine M. Klaskin Principal Financial Officer